Mesoblast Limited logo
Mesoblast Limited MESO
$ 16.8 -3.75%

Annual report 2022
added 08-31-2022

report update icon

Mesoblast Limited Balance Sheet 2011-2026 | MESO

Annual Balance Sheet Mesoblast Limited

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-50.2 M -126 M -68.8 M 30.9 M 21.6 M -45.8 M -80.9 M -144 M -196 M -315 M -207 M -263 M

Long Term Debt

7.08 M 8.48 M 57 M 67.3 M 59.4 M - - - - - - -

Long Term Debt Current

3.19 M 2.76 M 3.52 M - - - - - - - - -

Total Non Current Liabilities

114 M 69 M - 127 M 122 M 102 M 126 M 346 M 285 M 203 M 197 M 217 M

Total Liabilities

165 M 163 M 184 M 171 M 146 M 139 M 156 M 409 M 328 M 253 M 242 M 247 M

Deferred Revenue

- - - - - - - 19.5 M 15.9 M 16.2 M 28.2 M 27.1 M

Retained Earnings

-739 M -648 M -549 M -470 M -380 M -345 M -268 M -298 M -179 M -97.8 M -36.2 M 35 M

Total Assets

662 M 745 M 734 M 652 M 692 M 656 M 684 M 1.02 B 899 M 884 M 720 M 763 M

Cash and Cash Equivalents

60.4 M 137 M 129 M 50.4 M 37.8 M 45.8 M 80.9 M - - - - -

Book Value

497 M 581 M 549 M 481 M 546 M 517 M 528 M 609 M 572 M 630 M 479 M 516 M

Total Shareholders Equity

497 M 581 M 549 M 481 M 546 M 517 M 528 M - - - - -

All numbers in USD currency

Quarterly Balance Sheet Mesoblast Limited

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - - 8.05 M 7.94 M 7.56 M 8.48 M 6.48 M 6.51 M 7.05 M 6.32 M 5.76 M 6.68 M 3.92 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - 112 M 111 M 69.2 M 69 M 66.6 M 77.5 M 86.4 M 94.1 M 101 M 112 M 109 M 127 M 130 M 130 M - 122 M - - - 102 M - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

- - - 165 M 169 M 162 M 163 M 165 M 169 M 174 M 184 M 178 M 189 M 179 M 171 M 175 M 164 M - 146 M - - - 139 M - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- - - -717 M -696 M -670 M -648 M -626 M -599 M -573 M -549 M -516 M -501 M -476 M -470 M -449 M -424 M - -380 M - - - -345 M - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

- - - 682 M 704 M 722 M 745 M 766 M 687 M 713 M 734 M 666 M 690 M 654 M 652 M 676 M 688 M - 692 M - - - 656 M - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- - - 76.8 M 94.8 M 116 M 137 M 158 M 77.5 M 108 M 129 M 60.1 M 81.3 M 34.5 M 50.4 M 70.4 M 77 M 55.1 M 37.8 M 59.5 M 47.4 M - 45.8 M - - - 80.9 M - - - 111 M - - - - - - - - - - - - - - - - -

Book Value

- - - 517 M 536 M 560 M 581 M 601 M 519 M 539 M 549 M 488 M 501 M 475 M 481 M 501 M 525 M - 546 M - - - 517 M - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

- - - 517 M 536 M 560 M 581 M 601 M 519 M 539 M 549 M 488 M 501 M 475 M 481 M 501 M 525 M 528 M 546 M 556 M 576 M - 517 M - - - 528 M - - - 468 M - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Mesoblast Limited, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Adagene Adagene
ADAG
$ 1.9 -3.11 % $ 107 M chinaChina
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.31 -4.06 % $ 7.96 B australiaAustralia
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 25.87 -0.79 % $ 1.25 B usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 215.29 4.59 % $ 5 B danmarkDanmark
BioNTech SE BioNTech SE
BNTX
$ 105.97 -2.78 % $ 27.2 B germanyGermany
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.71 1.88 % $ 17 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 64.74 1.41 % $ 8.66 B usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.96 -1.0 % $ 8.62 B israelIsrael
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Burford Capital Limited Burford Capital Limited
BUR
$ 9.63 -0.93 % $ 1.56 B britainBritain
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.97 3.12 % $ 908 M israelIsrael
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Biogen Biogen
BIIB
$ 164.87 0.27 % $ 24 B usaUSA
Bio-Path Holdings Bio-Path Holdings
BPTH
- - $ 100 K usaUSA
BioVie BioVie
BIVI
$ 1.23 2.07 % $ 1.82 M usaUSA
Baudax Bio Baudax Bio
BXRX
- 0.59 % $ 63 K usaUSA
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA